Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases

Autor: Zitta Barrella Harboe, Sebastian Rask Hamm, Laura Pérez-Alós, Pradeesh Sivapalan, Helene Priemé, Torgny Wilcke, Peter Kjeldgaard, Saher Shaker, Alexander Svorre Jordan, Dina Leth Møller, Line Dam Heftdal, Johannes Roth Madsen, Rafael Bayarri-Olmos, Cecilie Bo Hansen, Mia Marie Pries-Heje, Rasmus Bo Hasselbalch, Kamille Fogh, Jose Juan Almagro Armenteros, Linda Hilsted, Erik Sørensen, Birgitte Lindegaard, Andrea Browatzki, Tor Biering-Sørensen, Ruth Frikke-Schmidt, Sisse Rye Ostrowski, Kasper Karmark Iversen, Henning Bundgaard, Susanne Dam Nielsen, Peter Garred, Jens-Ulrik Stæhr Jensen

Publikováno v: Harboe, Z B, Hamm, S R, Pérez-Alós, L, Sivapalan, P, Priemé, H, Wilcke, T, Kjeldgaard, P, Shaker, S, Svorre Jordan, A, Møller, D L, Heftdal, L D, Madsen, J R, Bayarri-Olmos, R, Hansen, C B, Pries-Heje, M M, Hasselbalch, R B, Fogh, K, Armenteros, J J A, Hilsted, L, Sørensen, E, Lindegaard, B, Browatzki, A, Biering-Sørensen, T, Frikke-Schmidt, R, Ostrowski, S R, Iversen, K K, Bundgaard, H, Nielsen, S D, Garred, P & Jensen, J-U S 2022, ' Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases ', BMJ Open Respiratory Research, vol. 9, no. 1 . https://doi.org/10.1136/bmjresp-2022-001268

IntroductionResponses to COVID-19 vaccination in patients with chronic pulmonary diseases are poorly characterised. We aimed to describe humoral responses following two doses of BNT162b2 mRNA COVID-19 vaccine and identify risk factors for impaired re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9ddeeacafcf47a95c6b134e08a78aaf
https://curis.ku.dk/portal/da/publications/antibody-responses-and-risk-factors-associated-with-impaired-immunological-outcomes-following-two-doses-of-bnt162b2-covid19-vaccination-in-patients-with-chronic-pulmonary-diseases(2799a7bf-7111-48b7-b169-690595caf295).html

Systemic corticosteroids and the risk of venous thromboembolism in COPD patients: A nationwide study of 30.473 outpatients with severe-very severe COPD

Autor: Ole Hilberg, Alexander Jordan, Howraman Meteran, Ema Rastoder, Mohamad Isam Saeed, Thyge L. Nielsen, Jon Torgny Wilcke, Pradeesh Sivapalan, Helene Priemé, Niels Seershol, Christian B. Laursen, Filip K. Knop, Uffe Bodtger, Nina S. Godtfredsen, Tor Biering-Sørensen, Josefin Eklöf, Julie Janner, Vibeke Gottlieb, Louise Lindhardt Tønnesen, Anders Løkke, Jens-Ulrik Stæhr Jensen, Jørn Carlsen

Publikováno v: Rastoder, E, Sivapalan, P, Eklöf, J, Saeed, M I, Jordan, A S, Meteran, H, Tønnesen, L, Biering-Sørensen, T, Løkke, A, Seershol, N, Nielsen, T L, Carlsen, J, Janner, J, Godtfredsen, N, Bødtger, U, Laursen, C, Hilberg, O, Knop, F K, Priemé, H, Gottlieb, V, Wilcke, J T & Jensen, J U S 2021, ' Systemic corticosteroids and the risk of venous thromboembolism in COPD patients: A nationwide study of 30.473 outpatients with severe-very severe COPD ', European Respiratory Journal. Supplement, vol. 58, no. suppl. 65, OA2590 . https://doi.org/10.1183/13993003.congress-2021.OA2590

Background: Due to repeated exacerbations a large group of patients with chronic obstructive pulmonary disease (COPD) are often exposed to oral corticosteroids (OCS). Corticosteroids may be thrombogenic. We evaluated the risk of venous thromboembolia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f686924487b7fed71d9d687499ba2a69
https://doi.org/10.1183/13993003.congress-2021.oa2590

Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19–a randomised double-blinded placebo-controlled trial

Autor: Andrea Browatzki, Helene Priemé, Therese S. Lapperre, Oliver Djurhuus Tupper, Pradeesh Sivapalan, Ida Steffensen, Christian Søborg, Casper Tidemandsen, Tor Biering-Sørensen, Dorthe Høgsberg, Jens-Ulrik Stæhr Jensen, Muhzda Ghanizada, Daniel Bech Rasmussen, Peter Lange, Uffe Bodtger, Asger Sverrild, Vibeke Gottlieb, Christina Marisa Bergsoe, Sidse Graff Jensen, Josefin Eklöf, Jens D Lundgren, Tobias Wirenfeldt Klausen, Martin Steen Frydland, Eva Brøndum, Alexander Jordan, Kjell Erik Julius Håkansson, Lars Egholm Pedersen, Charlotte Suppli Ulrik, Jon Torgny Wilcke, Howraman Meteran, Rasmus Dahlin Bojesen, Filip K. Knop

Publikováno v: The European Respiratory Journal
article-version (AM) Accepted Manuscript
Sivapalan, P, Suppli Ulrik, C, Sophie Lapperre, T, Dahlin Bojesen, R, Eklöf, J, Browatzki, A, Torgny Wilcke, J, Gottlieb, V, Julius Håkansson, K E, Tidemandsen, C, Tupper, O, Meteran, H, Bergsøe, C, Brøndum, E, Bodtger, U, Bech Rasmussen, D, Graff Jensen, S, Pedersen, L, Jordan, A, Priemé, H, Søborg, C, Steffensen, I E, Høgsberg, D, Wirenfeldt Klausen, T, Steen Frydland, M, Lange, P, Sverrild, A, Ghanizada, M, Krag Knop, F, Biering-Sørensen, T, Lundgren, J D, Stæhr Jensen, J-U & ProPAC-COVID study group 2022, ' Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19 : a randomised double-blinded placebo-controlled trial ', European Respiratory Journal, vol. 59, no. 1, 2100752 . https://doi.org/10.1183/13993003.00752-2021
Sivapalan, P & ProPAC-COVID writing group on behalf of the ProPAC-COVID Study Group 2022, ' Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19 : a randomised double-blinded placebo-controlled trial ', European Respiratory Journal, vol. 59, no. 1, 2100752 . https://doi.org/10.1183/13993003.00752-2021

Background Combining the antibiotic azithromycin and hydroxychloroquine induces airway immunomodulatory effects, with the latter also having in vitro antiviral properties. This may improve outcomes in patients hospitalised for COVID-19. Methods Place

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4323f34a71d948ef01854dabdd4e2c0
http://europepmc.org/articles/PMC8186006